Positive on Jubilant Life Sciences, Aurobindo Pharma: Ajay Bodke

Ajay Bodke of Prabhudas Lilladher told CNBC-TV18, "There are two companies in the pharmaceutical sector where almost all the inspections, all their plants have been inspected by the USFDA in last year. They have got an all the clearances. Hence the overhang that is devilling the performance of some of the stocks in pharmaceutical sector in our opinion does not hold true for these companies. The first is Jubilant Life Sciences, where we have a medium-term price target of Rs 578 with one-one and a half years perspective. Very strong earnings growth is expected in current year and in the next financial year." "The other stock we are positive on in the pharmaceutical space is Aurobindo Pharma where we believe that the stock has all the characteristics to outperform. A large number of strong US pipeline, the company has been getting approvals from most of its plants and so these two names in our opinion should be looked at," he said."So far as Sun Pharmaceutical Industries is concerned, our belief is that in the first quarter of next financial year, the company is expecting that the remedial measures that they have taken for the Halol Plant the USFDA inspection should happen and they are positively inclined that they should get an all clear. The biggest overhang on the stock is that once that gets cleared, the stock is in for a strong run," he added.